{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:01:23Z","timestamp":1788447683140,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tardive dyskinesia (TD) is a severe and persistent involuntary movement disorder associated with long-term antipsychotic treatment. TD is likely underreported and misdiagnosed in routine practice, and there is a need to understand the proportion of patients who may experience TD but receive no formal diagnosis. This information could support the characterisation of patient populations that may benefit from novel therapeutic interventions. This study aimed to identify and describe patients with diagnosed or undiagnosed TD. Demographic and clinical features associated with an ICD-9\/10 diagnosis of TD were explored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective study was conducted using de-identified electronic health record (EHR) data captured between 1999 and 2021 in the US. A cohort of 32,558 adults with schizophrenia-spectrum disorders, major depressive disorder with psychosis or bipolar disorder with psychosis who were prescribed antipsychotics was selected. Abnormal movements associated with TD and presence of TD documented in semi-structured EHR data were extracted through manual review of text recorded as part of the mental state examination. Patients with a recorded diagnosis of TD were identified based on the presence ICD-9\/10 codes within structured portions of medical records: ICD-9: 333.85; ICD-10: G24.01. Logistic regression was used to assess the association between patient characteristics and an ICD diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Altogether, 1,301 (4.0%) patients had either description of abnormal movements associated with TD (<jats:italic>n<\/jats:italic>=691) or documented TD (<jats:italic>n<\/jats:italic>=610) within semi-structured EHR data. Of those patients, only 64 (4.9%) had an ICD-TD diagnosis in structured EHR data. When the cohort was limited to those with documented TD in semi-structured EHR data, 56 (9.2%) had an ICD-TD diagnosis. Black\/African-American race was associated with lower odds of ICD diagnosis compared with white race (OR=0.46, 95%CI=0.20\u20130.95, <jats:italic>p<\/jats:italic>=0.04). Treatment in community mental health centres was associated with increased odds of an ICD diagnosis compared to an academic medical\u00a0centre (OR=adjusted OR=2.02, 95%CI=1.09\u20133.74, <jats:italic>p<\/jats:italic>=0.03).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study highlights a pressing need for clinicians to better recognise and diagnose TD, which in turn may contribute to increased access to treatments for patients. A recorded ICD diagnosis of TD may be driven by factors related to both the patient and clinical setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-025-06780-w","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T16:54:27Z","timestamp":1745254467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-086X","authenticated-orcid":false,"given":"Kira","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-8788","authenticated-orcid":false,"given":"Rashmi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"4","key":"6780_CR1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/jcm12041498","volume":"12","author":"S Badarny","year":"2023","unstructured":"Badarny S, Nassar R, Badarny Y. Tardive syndrome is a mysterious phenomenon with different clinical manifestations. J Clin Med. 2023;12(4):1498.","journal-title":"J Clin Med"},{"issue":"43","key":"6780_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21430","volume":"21","author":"H Bergman","year":"2017","unstructured":"Bergman H, Walker D-M, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017;21(43):1\u2013218.","journal-title":"Health Technol Assess"},{"key":"6780_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2307\/2136311","volume":"27","author":"P Brown","year":"1986","unstructured":"Brown P, Funk SC. Tardive dyskinesia: Barriers to the professional recognition of an iatrogenic disease. J Health Soc Behav. 1986;27:116\u201332.","journal-title":"J Health Soc Behav."},{"issue":"3","key":"6780_CR4","doi-asserted-by":"publisher","first-page":"20738","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):20738.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"6780_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330\u201340.","journal-title":"World Psychiatry"},{"key":"6780_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2147\/NDT.S196541","volume":"15","author":"SN Caroff","year":"2019","unstructured":"Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785\u201394.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"3","key":"6780_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/JCP.0000000000001201","volume":"40","author":"SN Caroff","year":"2020","unstructured":"Caroff SN, Yeomans K, Lenderking WR, Cutler AJ, Tanner CM, Shalhoub H, Pag\u00e9 V, Chen J, Franey E, Yonan C. RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40(3):259.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"6780_CR8","first-page":"535","volume":"153","author":"D Casey","year":"1990","unstructured":"Casey D. Tardive dyskinesia. West J Med. 1990;153(5):535.","journal-title":"West J Med"},{"key":"6780_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jns.2018.02.037","volume":"389","author":"L Citrome","year":"2018","unstructured":"Citrome L. Reprint of: Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2018;389:61\u20136.","journal-title":"J Neurol Sci"},{"issue":"8","key":"6780_CR10","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.4088\/JCP.tv17016ah4c","volume":"78","author":"CU Correll","year":"2017","unstructured":"Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78(8):6536.","journal-title":"J Clin Psychiatry"},{"key":"6780_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2018.11.017","volume":"59","author":"K Frei","year":"2019","unstructured":"Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019;59:151\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"6780_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1600-0447.1988.tb05138.x","volume":"77","author":"J Gerlach","year":"1988","unstructured":"Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand. 1988;77(4):369\u201378.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"6780_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1017\/S109285292000200X","volume":"27","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, Caroff SN, Lundt L. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27(2):208\u201317.","journal-title":"CNS Spectr"},{"issue":"2","key":"6780_CR14","doi-asserted-by":"publisher","first-page":"20745","DOI":"10.4088\/JCP.nu17034ah1c","volume":"79","author":"R Jain","year":"2018","unstructured":"Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;79(2):20745.","journal-title":"J Clin Psychiatry"},{"key":"6780_CR15","unstructured":"Jones RS, Walsh PG, Sturmey P. (1995). Stereotyped movement disorders. (No Title)."},{"key":"6780_CR16","first-page":"179","volume":"12","author":"A Kumsa","year":"2020","unstructured":"Kumsa A, Girma S, Alemu B, Agenagnew L. Psychotropic medications-induced tardive dyskinesia and associated factors among patients with mental illness in Ethiopia. Clin Pharmacol. 2020;12:179\u201387.","journal-title":"Clin Pharmacol"},{"issue":"6","key":"6780_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","volume":"173","author":"RD Lane","year":"1985","unstructured":"Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173(6):353\u20137.","journal-title":"J Nerv Ment Dis"},{"key":"6780_CR18","unstructured":"Leo S, Maughn K, Miller A, Shoaib S, Reshef S. Tardive dyskinesia: epidemiological trends in US populations based on cross-sectional analysis of retrospective claims data. n.d. Presented at the 35th Annual Psych Congress; September 17\u201320, 2022; New Orleans, Louisiana."},{"issue":"6","key":"6780_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/pcn.12270","volume":"69","author":"PP Lerner","year":"2015","unstructured":"Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321\u201334.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"6780_CR20","doi-asserted-by":"publisher","first-page":"e0216044","DOI":"10.1371\/journal.pone.0216044","volume":"14","author":"AM Loughlin","year":"2019","unstructured":"Loughlin AM, Lin N, Abler V, Carroll B. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PLoS ONE. 2019;14(6):e0216044.","journal-title":"PLoS ONE"},{"key":"6780_CR21","volume-title":"Clinical methods: the history, physical, and laboratory examinations","author":"DC Martin","year":"1990","unstructured":"Martin DC. The mental status examination. In: Clinical methods: the history, physical, and laboratory examinations. 3rd ed.\u00a01990.","edition":"3"},{"issue":"4","key":"6780_CR22","doi-asserted-by":"publisher","first-page":"41627","DOI":"10.4088\/PCC.21m03069","volume":"24","author":"CS North","year":"2022","unstructured":"North CS, McDonald K, Hunter J, Burruss J. Prevalence of tardive dyskinesia in an electronic medical record study at a large community mental health treatment center. Prim Care Companion CNS Disord. 2022;24(4):41627.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"5","key":"6780_CR23","doi-asserted-by":"publisher","first-page":"e017451","DOI":"10.1016\/j.heliyon.2019.e01745","volume":"5","author":"RS Patel","year":"2019","unstructured":"Patel RS, Mansuri Z, Chopra A. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: a nationwide case-control study. Heliyon. 2019;5(5):e017451.","journal-title":"Heliyon"},{"key":"6780_CR24","doi-asserted-by":"crossref","unstructured":"Patel R, Wee SN, Ramaswamy R, Thadani S, Tandi J, Garg R, Kollins SH. NeuroBlu, an\u00a0electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world\u00a0data. BMJ Open. 2022;12(4):e057227.","DOI":"10.1136\/bmjopen-2021-057227"},{"key":"6780_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5334\/tohm.585","volume":"10","author":"VD Sharma","year":"2020","unstructured":"Sharma VD, Gupta HV, Espay AJ. Copulatory dyskinesia: pathognomonic manifestation of tardive dyskinesia. Tremor Other Hyperkinet Mov. 2020;10:56.","journal-title":"Tremor Other Hyperkinet Mov."},{"key":"6780_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","volume":"389","author":"M Solmi","year":"2018","unstructured":"Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018a;389:21\u20137.","journal-title":"J Neurol Sci"},{"key":"6780_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2147\/DDDT.S133205","volume":"12","author":"M Solmi","year":"2018","unstructured":"Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018b;12:1215\u201338.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"6780_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1017\/S1092852917000542","volume":"23","author":"M Strassnig","year":"2018","unstructured":"Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23(6):370\u20137.","journal-title":"CNS Spectr"},{"issue":"Spring","key":"6780_CR29","first-page":"1","volume":"10","author":"M Topaz","year":"2013","unstructured":"Topaz M, Shafran-Topaz L, Bowles KH. ICD-9 to ICD-10: evolution, revolution, and current debates in the United States. Perspect Health Inf Manag. 2013;10(Spring):1.","journal-title":"Perspect Health Inf Manag"},{"key":"6780_CR30","doi-asserted-by":"crossref","unstructured":"Turner M. Annotation: Repetitive behaviour in autism: A review of psychological research. J Child Psychol Psychiatry. 1999;40(6):839\u201349.","DOI":"10.1017\/S0021963099004278"},{"key":"6780_CR31","doi-asserted-by":"publisher","first-page":"102877","DOI":"10.1016\/j.ajp.2021.102877","volume":"66","author":"K Uludag","year":"2021","unstructured":"Uludag K, Wang DM, Goodman C, Wang L, Zhang X. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia. Asian J Psychiatr. 2021;66:102877.","journal-title":"Asian J Psychiatr"},{"key":"6780_CR32","first-page":"tre-03-161-4138","volume":"3","author":"O Waln","year":"2013","unstructured":"Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 2013;3:tre-03-161-4138-1.","journal-title":"Tremor Other Hyperkinet Mov"},{"issue":"6","key":"6780_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/01.jcp.0000144888.43449.54","volume":"24","author":"I Wonodi","year":"2004","unstructured":"Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol. 2004;24(6):592\u20138.","journal-title":"J Clin Psychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06780-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T16:54:29Z","timestamp":1745254469000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06780-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6780"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06780-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments. The version of NeuroBlu used contained de-identified data from the MindLinc EHR. For the MindLinc EHR, institutional review board (IRB) approval for this study was not required because MindLinc data are anonymised and thus exempt from Health Insurance Portability and Accountability Act requirements. The NeuroBlu Database platform has received a waiver of informed consent prior to study conduct from the WCG Institutional Review Board (Ref: The Holmusk Real-World Evidence Parent Protocol; IRB registration number 1\u20131470336-1; Protocol ID HolmuskRWE_1.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"At the time of this study,\u00a0KG,\u00a0and YW\u00a0report employment with and equity ownership in KKT Technologies Pte. Ltd. or its subsidiaries. RP, MR, ZL and LW are previous employees of Holmusk Technologies Inc.\nRP has received grant funding from the National Institute for Health and Care Research (NIHR301690), the Medical Research Council (MR\/S003118\/1). RP has been a Scientific Advisory Board member for Boehringer Ingelheim, has received grant funding from Janssen, and has received consulting fees from Holmusk, Akrivia Health, Columbia Data Analytics, Clinilabs, Social Finance, Boehringer Ingelheim, Bristol Myers Squibb, Teva and Otsuka. CC has been a consultant and\/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}